Therapeutic targets for the treatment of microsporidiosis in humans

Bing Han, Louis M. Weiss

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Microsporidia have been increasingly reported to infect humans. The most common presentation of microsporidiosis is chronic diarrhea, a significant mortality risk in immune-compromised patients. Albendazole, which inhibits tubulin, and fumagillin, which inhibits methionine aminopeptidase type 2 (MetAP2), are the two main therapeutic agents used for treatment of microsporidiosis. In addition, to their role as emerging pathogens in humans, microsporidia are important pathogens in insects, aquaculture, and veterinary medicine. New therapeutic targets and therapies have become a recent focus of attention for medicine, veterinary, and agricultural use. Areas covered: Herein, we discuss the detection and symptoms of microsporidiosis in humans and the therapeutic targets that have been utilized for the design of new drugs for the treatment of this infection, including triosephosphate isomerase, tubulin, MetAP2, topoisomerase IV, chitin synthases, and polyamines. Expert opinion: Enterocytozoon bieneusi is the most common microsporidia in human infection. Fumagillin has a broader anti-microsporidian activity than albendazole and is active against both Ent. bieneusi and Encephaliozoonidae. Microsporidia lack methionine aminopeptidase type 1 and are, therefore, dependent on MetAP2, while mammalian cells have both enzymes. Thus, MetAP2 is an essential enzyme in microsporidia and new inhibitors of this pathway have significant promise as therapeutic agents.

Original languageEnglish (US)
Pages (from-to)903-915
Number of pages13
JournalExpert Opinion on Therapeutic Targets
Volume22
Issue number11
DOIs
StatePublished - Nov 2 2018

Fingerprint

Microsporidiosis
Microsporidia
Veterinary medicine
Albendazole
Pathogens
Tubulin
Enterocytozoon
DNA Topoisomerase IV
Chitin Synthase
Triose-Phosphate Isomerase
Veterinary Medicine
Aquaculture
Aminopeptidases
Polyamines
Enzymes
Therapeutics
Methionine
Cells
Drug Design
Expert Testimony

Keywords

  • Chitin synthases
  • diagnosis
  • methionine aminopeptidase 2
  • Microsporidia
  • microsporidiosis
  • polyamines
  • therapeutic targets
  • triosephosphate isomerase
  • tubulin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Therapeutic targets for the treatment of microsporidiosis in humans. / Han, Bing; Weiss, Louis M.

In: Expert Opinion on Therapeutic Targets, Vol. 22, No. 11, 02.11.2018, p. 903-915.

Research output: Contribution to journalReview article

@article{35e4c985a408403c86ecf4f823c2347c,
title = "Therapeutic targets for the treatment of microsporidiosis in humans",
abstract = "Introduction: Microsporidia have been increasingly reported to infect humans. The most common presentation of microsporidiosis is chronic diarrhea, a significant mortality risk in immune-compromised patients. Albendazole, which inhibits tubulin, and fumagillin, which inhibits methionine aminopeptidase type 2 (MetAP2), are the two main therapeutic agents used for treatment of microsporidiosis. In addition, to their role as emerging pathogens in humans, microsporidia are important pathogens in insects, aquaculture, and veterinary medicine. New therapeutic targets and therapies have become a recent focus of attention for medicine, veterinary, and agricultural use. Areas covered: Herein, we discuss the detection and symptoms of microsporidiosis in humans and the therapeutic targets that have been utilized for the design of new drugs for the treatment of this infection, including triosephosphate isomerase, tubulin, MetAP2, topoisomerase IV, chitin synthases, and polyamines. Expert opinion: Enterocytozoon bieneusi is the most common microsporidia in human infection. Fumagillin has a broader anti-microsporidian activity than albendazole and is active against both Ent. bieneusi and Encephaliozoonidae. Microsporidia lack methionine aminopeptidase type 1 and are, therefore, dependent on MetAP2, while mammalian cells have both enzymes. Thus, MetAP2 is an essential enzyme in microsporidia and new inhibitors of this pathway have significant promise as therapeutic agents.",
keywords = "Chitin synthases, diagnosis, methionine aminopeptidase 2, Microsporidia, microsporidiosis, polyamines, therapeutic targets, triosephosphate isomerase, tubulin",
author = "Bing Han and Weiss, {Louis M.}",
year = "2018",
month = "11",
day = "2",
doi = "10.1080/14728222.2018.1538360",
language = "English (US)",
volume = "22",
pages = "903--915",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Therapeutic targets for the treatment of microsporidiosis in humans

AU - Han, Bing

AU - Weiss, Louis M.

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Introduction: Microsporidia have been increasingly reported to infect humans. The most common presentation of microsporidiosis is chronic diarrhea, a significant mortality risk in immune-compromised patients. Albendazole, which inhibits tubulin, and fumagillin, which inhibits methionine aminopeptidase type 2 (MetAP2), are the two main therapeutic agents used for treatment of microsporidiosis. In addition, to their role as emerging pathogens in humans, microsporidia are important pathogens in insects, aquaculture, and veterinary medicine. New therapeutic targets and therapies have become a recent focus of attention for medicine, veterinary, and agricultural use. Areas covered: Herein, we discuss the detection and symptoms of microsporidiosis in humans and the therapeutic targets that have been utilized for the design of new drugs for the treatment of this infection, including triosephosphate isomerase, tubulin, MetAP2, topoisomerase IV, chitin synthases, and polyamines. Expert opinion: Enterocytozoon bieneusi is the most common microsporidia in human infection. Fumagillin has a broader anti-microsporidian activity than albendazole and is active against both Ent. bieneusi and Encephaliozoonidae. Microsporidia lack methionine aminopeptidase type 1 and are, therefore, dependent on MetAP2, while mammalian cells have both enzymes. Thus, MetAP2 is an essential enzyme in microsporidia and new inhibitors of this pathway have significant promise as therapeutic agents.

AB - Introduction: Microsporidia have been increasingly reported to infect humans. The most common presentation of microsporidiosis is chronic diarrhea, a significant mortality risk in immune-compromised patients. Albendazole, which inhibits tubulin, and fumagillin, which inhibits methionine aminopeptidase type 2 (MetAP2), are the two main therapeutic agents used for treatment of microsporidiosis. In addition, to their role as emerging pathogens in humans, microsporidia are important pathogens in insects, aquaculture, and veterinary medicine. New therapeutic targets and therapies have become a recent focus of attention for medicine, veterinary, and agricultural use. Areas covered: Herein, we discuss the detection and symptoms of microsporidiosis in humans and the therapeutic targets that have been utilized for the design of new drugs for the treatment of this infection, including triosephosphate isomerase, tubulin, MetAP2, topoisomerase IV, chitin synthases, and polyamines. Expert opinion: Enterocytozoon bieneusi is the most common microsporidia in human infection. Fumagillin has a broader anti-microsporidian activity than albendazole and is active against both Ent. bieneusi and Encephaliozoonidae. Microsporidia lack methionine aminopeptidase type 1 and are, therefore, dependent on MetAP2, while mammalian cells have both enzymes. Thus, MetAP2 is an essential enzyme in microsporidia and new inhibitors of this pathway have significant promise as therapeutic agents.

KW - Chitin synthases

KW - diagnosis

KW - methionine aminopeptidase 2

KW - Microsporidia

KW - microsporidiosis

KW - polyamines

KW - therapeutic targets

KW - triosephosphate isomerase

KW - tubulin

UR - http://www.scopus.com/inward/record.url?scp=85056142670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056142670&partnerID=8YFLogxK

U2 - 10.1080/14728222.2018.1538360

DO - 10.1080/14728222.2018.1538360

M3 - Review article

VL - 22

SP - 903

EP - 915

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 11

ER -